Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Vlado PerkovicRobert TotoMark E CooperJohannes F E MannJulio RosenstockDarren K McGuireSteven E KahnNikolaus MarxJohn H AlexanderBernard ZinmanEgon PfarrSven SchnaidtThomas MeinickeMaximillian von EynattenJyothis T GeorgeOdd Erik JohansenChristoph Wannernull nullPublished in: Diabetes care (2020)
Across all GFR categories, in participants with type 2 diabetes and CKD and/or CV disease, there was no difference in risk for linagliptin versus placebo on CV and kidney events. Significant reductions in risk for albuminuria progression and HbA1c and no difference in AEs were observed.